Form 4: Teva Pharmaceutical Industries: Chief Accounting Officer Reports Share Transactions

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent disposal of ordinary shares.

Summary

• On March 5, 2024, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries, had 3,564 restricted share units vest.
• These units converted into 3,564 ordinary shares.
• Following the transaction, Weiss directly owns 3,566 ordinary shares and indirectly owns 33,314 ordinary shares.
• The transaction was reported on March 7, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing share transactions, with neutral sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and share ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages including restricted share units are standard practice among publicly traded pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson.
• The vesting schedules and terms of these units are typically benchmarked against industry peers to attract and retain talent.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.

Key Dates